The best of R&I and around the web, handpicked by our editors.
White papers, service directory and conferences for the R&I community.
Web replica of the print magazine.
Insurers blame ‘pay-for-delay’ for skyrocketing drug prices, but manufacturers insist settlements help control costs.
The search for a COVID-19 vaccine is on. Hopefully, advancements in artificial intelligence will make the time required to produce a vaccine shorter.
This year, six brokers from across the brokerage field were named as the 2020 Pharmaceuticals Power Broker winners. An additional two brokers were named as finalists.
Silvia Sacalis of Healthesystems details the different aspects of holistic care for injured workers and why each is important for a successful return-to-work.
The poisonous actions of pharma companies peddling painkillers are a social scourge that cannot be accepted.
Pharmaceutical companies and their insurers should brace themselves as the opioid litigation rages ahead.
A new decision out of Texas aims to hold PBMs accountable for their role in perpetuating the epidemic. Other municipalities are likely to follow suit.
Lawsuits against drug makers may be necessary, but to what degree do they aid addicted injured workers?
The rapid-fire advances and increased adoption of smart technology will change the way manufacturers detect and respond to product recalls.